All In Biotech

Drug Trial Radar · NCT07242781

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

A Phase 1, Open-label, 2-part, Fixed-sequence, Crossover Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of AR-LDD (BMS-986365) in Healthy Adult Male Participants

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

22

Actual

Start

Dec 15, 2025

Primary completion

Apr 9, 2026

Study completion Apr 21, 2026

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.

Conditions

  • Healthy Volunteers

Interventions

  • BMS-986365Drug

    Specified dose on specified days

  • ItraconazoleDrug

    Specified dose on specified days

  • RifampinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of BMS-986365Time frame: Up to approximately Day 32
  2. Part A: Cmax of BMS-986365 Without ItraconazoleTime frame: Up to approximately Day 32
  3. Part A: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986365 With ItraconazoleTime frame: Up to approximately Day 32
  4. Part A: AUC(0-T) of BMS-986365 Without ItraconazoleTime frame: Up to approximately Day 32
  5. Part A: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986365Time frame: Up to approximately Day 32
  6. Part A: AUC(INF) of BMS-986365 Without ItraconazoleTime frame: Up to approximately Day 32
  7. Part B: Cmax of BMS-986365 With RifampinTime frame: Up to approximately Day 37
  8. Part B: Cmax of BMS-986365 Without RifampinTime frame: Up to approximately Day 37
  9. Part B: AUC(INF) of BMS-986365 With RifampinTime frame: Up to approximately Day 37
  10. Part B: AUC(INF) of BMS-986365 Without RifampinTime frame: Up to approximately Day 37
  11. Part B: AUC(0-T) of BMS-986365 With RifampinTime frame: Up to approximately Day 37
  12. Part B: AUC(0-T) of BMS-986365 Without RifampinTime frame: Up to approximately Day 37

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.